Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study.

Overall, there was a significant trend toward using 300 mg as a starting dose as the treatment line progressed, a pattern that was more marked in PsA patients ( p < 0.001) than in AxSpA patients ( p = 0.038).

also in 9,775 other papers

After 1 year of treatment, patients diagnosed with PsA were less likely to persist with secukinumab than those with AxSpA with an HR of 12.32 (95% CI 1.6–94.9, p = 0.016), obese patients showed a non-significant trend to discontinuation with respect to the non-obese with an HR of 2.54 (95% CI 0.99–6.50, p = 0.051) and women showed a trend toward a better retention rate that men with an HR of 0.29 (95% CI 0.04–2.28, p = 0.241).

also in 53,322 other papers

In fact, in our study gender and obesity did not reach statistical significance in the multivariate analysis but showed a very important effect when included in the interaction study.

also in 111,027 other papers